Mucinous Adenocarcinoma of the Ovary

被引：3

作者：

Sholi, Abdalla

Martino, Martin M.

Pirigyi, Megan

Rosenblum, Norman G.

Markman, Maurie

Peterson, Candace S.

Bradbury, Angela R. ^{[3
]}

Morris, Gloria J. ^{[1
,2
]}

机构：

[1] Hematol & Oncol Associates NE PA, PC, Dunmore, PA 18512 USA

[2] Commonwealth Med Coll, Scranton, PA USA

[3] Fox Chase Canc Ctr, Dept Clin Genet, Philadelphia, PA 19111 USA

来源：

SEMINARS IN ONCOLOGY | 2010年 / 37卷 / 04期

关键词：

PHASE-III TRIAL; INTRAPERITONEAL CHEMOTHERAPY; CANCER; PACLITAXEL; 5-FLUOROURACIL; OXALIPLATIN; CARBOPLATIN; CARCINOMA; CISPLATIN; MUTATIONS;

D O I：

10.1053/j.seminoncol.2010.06.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：314 / 320

页数：7

共 25 条

[11] Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management [J].

Lynch, Henry T. ;

Casey, Murray Joseph ;

Snyder, Carrie L. ;

Bewtra, Chhanda ;

Lynch, Jane F. ;

Butts, Matthew ;

Godwin, Andrew K. .

MOLECULAR ONCOLOGY, 2009, 3 (02) :97-137

[12] Intraperitoneal chemotherapy of ovarian cancer: A review, with a focus on practical aspects of treatment [J].

Markman, M ;

Walker, JL .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :988-994

[13] Results of the 2006 Innsbruck International Consensus Conference on Intraperitoneal Chemotherapy in patients with Ovarian Cancer [J].

Marth, Christian ;

Walker, Joan L. ;

Barakat, Richard R. ;

Casado, Antonio ;

Gadducci, Angiolo ;

Miller, Brigitte ;

Odicino, Franco ;

Pujade-Lauraine, Eric ;

Sehouli, Jalid ;

Trope, Claes ;

Wenzel, Lari ;

Zeimet, Alain G. .

CANCER, 2007, 109 (04) :645-649

[14]

*NAT COMPR CANC NE, PRACT GUID ONC VERS

[15] Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer [J].

Negri, FV ;

Wotherspoon, A ;

Cunningham, D ;

Norman, AR ;

Chong, G ;

Ross, PJ .

ANNALS OF ONCOLOGY, 2005, 16 (08) :1305-1310

[16] Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study [J].

Ozols, RF ;

Bundy, BN ;

Greer, BE ;

Fowler, JM ;

Clarke-Pearson, D ;

Burger, RA ;

Mannel, RS ;

DeGeest, K ;

Hartenbach, EM ;

Baergen, R .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3194-3200

[17] BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases [J].

Pal, T ;

Permuth-Wey, J ;

Betts, JA ;

Krischer, JP ;

Fiorica, J ;

Arango, H ;

LaPolla, J ;

Hoffman, M ;

Martino, MA ;

Wakeley, K ;

Wilbanks, G ;

Nicosia, S ;

Cantor, A ;

Sutphen, R .

CANCER, 2005, 104 (12) :2807-2816

[18] Advanced stage mucinous epithelial ovarian cancer: The Hellenic cooperative oncology group experience [J].

Pectasides, D ;

Fountzilas, G ;

Aravantinos, G ;

Kalofonos, HP ;

Efstathiou, E ;

Salamalekis, E ;

Farmakis, D ;

Skarlos, D ;

Briasoulis, E ;

Economopoulos, T ;

Dimopoulos, MA .

GYNECOLOGIC ONCOLOGY, 2005, 97 (02) :436-441

[19] Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study [J].

Pectasides, D ;

Pectasides, M ;

Farmakis, D ;

Gaglia, A ;

Kournarianou, A ;

Nikolaou, M ;

Kournpou, M ;

Kountourakis, P ;

Papaxoinis, G ;

Mitrou, P ;

Econornopoulos, T ;

Raptis, SA .

GYNECOLOGIC ONCOLOGY, 2004, 95 (01) :165-172

[20] Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1 [J].

Rubin, SC ;

Benjamin, I ;

Behbakht, K ;

Takahashi, H ;

Morgan, MA ;

LiVolsi, VA ;

Berchuck, A ;

Muto, MG ;

Garber, JE ;

Weber, BL ;

Lynch, HT ;

Boyd, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (19) :1413-1416

← 1 2 3 →